The effect of stimulation therapy and donepezil on cognitive function in Alzheimer's disease. A community based RCT with a two-by-two factorial design.
BACKGROUND
Progressive neurodegeneration in Alzheimer's disease (AD) induces cognitive deterioration, and there is controversy regarding the optimal treatment strategy in early AD. Stimulation therapy, including physical exercise and cholinesterase inhibitors are both reported to postpone cognitive deterioration in separate studies. We aimed to study the effect of stimulation therapy and the additional effect of donepezil on cognitive function in early AD.


METHODS



METHODS
A two-by-two factorial trial comprising stimulation therapy for one year compared to standard care to which a randomized double-blinded placebo controlled trial with donepezil was added.


METHODS
Nine rural municipalities in Northern Norway.


METHODS
187 participants 65 years and older with a recent diagnosis of mild or moderate AD were included in the study of which 146 completed a one-year follow-up.


METHODS
In five municipalities the participants received stimulation therapy whereas participants in four received standard care. All participants were randomised double-blindly to donepezil or placebo and tested with three different cognitive tests four times during the one-year study period.


RESULTS
Changes in MMSE sum score.Secondary outcome: Changes in ADAS-Cog and Clock Drawing Test.


RESULTS
MMSE scores remained unchanged amongst AD participants receiving stimulation therapy and those receiving standard care. The results were consistent for ADAS-Cog and Clock Drawing Test. No time trend differences were found during one-year follow-up between groups receiving stimulation therapy versus standard care or between donepezil versus placebo.


CONCLUSIONS
In rural AD patients non-pharmacological and pharmacological therapy did not improve outcome compared with standard care but all groups retained cognitive function during one year follow-up. Other studies are needed to confirm these results.


BACKGROUND
ClinicalTrials.gov (Identifier: NCT00443014). EudraCT database (no 2004-002613-37).
Department of Community Medicine, University of Tromsø, Norway. frea@online.no
Fred
F
Andersen
Matti
M
Viitanen
Dag S
DS
Halvorsen
Bjørn
B
Straume
Tom
T
Wilsgaard
Torgeir A
TA
Engstad
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000453:epidemiology* / Q000628:therapy*; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage; D003072:Cognition Disorders / Q000453:epidemiology* / Q000628:therapy*; D003131:Combined Modality Therapy; D015897:Comorbidity; D000077265:Donepezil; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007189:Indans / Q000008:administration & dosage*; D008297:Male; D009664:Norway / Q000453:epidemiology; D026741:Physical Therapy Modalities / Q000706:statistics & numerical data*; D010880:Piperidines / Q000008:administration & dosage*; D015995:Prevalence; D016896:Treatment Outcome
D002800:Cholinesterase Inhibitors; D007189:Indans; D010880:Piperidines; D000077265:Donepezil